$Cingulate (CING.US)$ Note: The patent covers up to 30 Europ...

$Cingulate (CING.US)$ Note: The patent covers up to 30 European regions, including the UK, and marks a key step in Cingulate's efforts to solidify its influence in the global ADHD market. Cingulate is also preparing to submit a New Drug Application (NDA) to the US Food and Drug Administration.

The drug is designed using Cingulate's Precise Timed Release Technology, which allows for precise timed release of the drug three times throughout the day. This innovation aims to provide patients with a full day of treatment with just one pill, and addresses ADHD treatment